OBJECTIVES: Rapid diagnosis and appropriate empirical antimicrobial therapy before the availability of conventional microbiological results is of pivotal importance for the clinical outcome of ventilator-associated pneumonia (VAP). We evaluated the VAPChip, a novel, closed cartridge molecular tool aiming to identify directly from clinical samples and within a working day the principal bacteria causative of VAP as well as clinically relevant β-lactam resistance genes. METHODS: The Real-time Array PCR for Infectious Diseases (RAP-ID) is a novel technology that combines multiplex PCR with real-time microarray detection. The VAPChip is a closed cartridge kit adapted to the RAP-ID instrument that targets 13 key respiratory pathogens causative of VAP and 24 relevant antimicrobial resistance genes that mediate resistance to β-lactam agents, including extended-spectrum cephalosporins and carbapenems. Analytical validation of the VAPChip was carried out blindly on a collection of 292 genotypically characterized bacterial reference and clinical isolates, including 225 isolates selected on the basis of their species identification and antimicrobial resistance profiles and 67 bacterial isolates belonging to the oropharyngeal flora not targeted by the array. RESULTS: The limit of detection of the assay lies between 10 and 100 genome copies/PCR and the dynamic range is five orders of magnitude permitting at least semi-quantitative reporting of the results. Sensitivity, specificity and negative and positive predictive values ranged from 95.8% to 100% for species identification and detection of resistance genes. CONCLUSIONS: VAPChip is a novel diagnostic tool able to identify resistant bacterial isolates by RAP-ID technology. The results of this analytical validation have to be confirmed on clinical specimens.
OBJECTIVES: Rapid diagnosis and appropriate empirical antimicrobial therapy before the availability of conventional microbiological results is of pivotal importance for the clinical outcome of ventilator-associated pneumonia (VAP). We evaluated the VAPChip, a novel, closed cartridge molecular tool aiming to identify directly from clinical samples and within a working day the principal bacteria causative of VAP as well as clinically relevant β-lactam resistance genes. METHODS: The Real-time Array PCR for Infectious Diseases (RAP-ID) is a novel technology that combines multiplex PCR with real-time microarray detection. The VAPChip is a closed cartridge kit adapted to the RAP-ID instrument that targets 13 key respiratory pathogens causative of VAP and 24 relevant antimicrobial resistance genes that mediate resistance to β-lactam agents, including extended-spectrum cephalosporins and carbapenems. Analytical validation of the VAPChip was carried out blindly on a collection of 292 genotypically characterized bacterial reference and clinical isolates, including 225 isolates selected on the basis of their species identification and antimicrobial resistance profiles and 67 bacterial isolates belonging to the oropharyngeal flora not targeted by the array. RESULTS: The limit of detection of the assay lies between 10 and 100 genome copies/PCR and the dynamic range is five orders of magnitude permitting at least semi-quantitative reporting of the results. Sensitivity, specificity and negative and positive predictive values ranged from 95.8% to 100% for species identification and detection of resistance genes. CONCLUSIONS: VAPChip is a novel diagnostic tool able to identify resistant bacterial isolates by RAP-ID technology. The results of this analytical validation have to be confirmed on clinical specimens.
Authors: S Roisin; T-D Huang; R de Mendonça; C Nonhoff; P Bogaerts; M Hites; B Delaere; S Hamels; F de Longueville; Y Glupczynski; O Denis Journal: Eur J Clin Microbiol Infect Dis Date: 2017-09-27 Impact factor: 3.267
Authors: Marin H Kollef; Matteo Bassetti; Bruno Francois; Jason Burnham; George Dimopoulos; Jose Garnacho-Montero; Jeffrey Lipman; Charles-Edouard Luyt; David P Nicolau; Maarten J Postma; Antonio Torres; Tobias Welte; Richard G Wunderink Journal: Intensive Care Med Date: 2017-02-04 Impact factor: 17.440
Authors: Themoula Charalampous; Gemma L Kay; Hollian Richardson; Alp Aydin; Rossella Baldan; Christopher Jeanes; Duncan Rae; Sara Grundy; Daniel J Turner; John Wain; Richard M Leggett; David M Livermore; Justin O'Grady Journal: Nat Biotechnol Date: 2019-06-24 Impact factor: 54.908
Authors: N J Gadsby; M P McHugh; C D Russell; H Mark; A Conway Morris; I F Laurenson; A T Hill; K E Templeton Journal: Clin Microbiol Infect Date: 2015-05-14 Impact factor: 8.067
Authors: Naomi J Gadsby; Clark D Russell; Martin P McHugh; Harriet Mark; Andrew Conway Morris; Ian F Laurenson; Adam T Hill; Kate E Templeton Journal: Clin Infect Dis Date: 2016-01-07 Impact factor: 9.079